Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Liked2Thinkon Aug 16, 2022 11:34pm
111 Views
Post# 34901169

RE:RE:RE:RE:RE:RE:I don't see any defamation on this stockhouse board

RE:RE:RE:RE:RE:RE:I don't see any defamation on this stockhouse boardI cannot follow how you are taking this as a win.

You are making it sound like Stagezero knew their stock was going to crater over 90% and that is why they were ok with giving CARE 14.9 million shares.  You cannot pick your time later on and say that its the same thing.

Stage bought CARE for 14.9 million and the value of CARE is down 13.6 million.  What other company would give Stage 10-15 million for CARE today?  No one

Also I cannot honestly believe anyone wants to short this stock still.  What is the point its 9 friggin cents!  Now would be the time to go away and pump this thing back up so they could re short it all over agin.  Why would they be worried about Stage being profitable.  Again who shorts a 9 cent stock?




LithLover wrote: Care Oncology brought in nearly $1 million per quarter and Stage acquired it for 14.9 million shares or at today's price of $1.3 million. A company worth $10-15 million for $1.3 million.

Stage is using the Covid revenue and now Care Oncology revenue to maintain operations and scale out Aristotle.  You obviously have never owned a company or been an executive before.

The improvement by quarter, the pivot into Covid and acquistion of Care Oncology were excellent moves.  Aristotle will get traction and if you were listening to the CC or read the MD&A you would understand how Aristotle is growing.  

This should not be at these near 52 week lows but you can see the spamming and need to bury posts from the bashers.  Ask why they feel the need to continually post today?   If the company was done as they suggest the board would dry up and they would move on.  They want to short, they want to keep the SP down for the toxic fianciers but Tripp has the means to keep revenue growing with Care Oncology and will move the funds into Aristotle scale out.

The company is taking steps to profitability and they are getting worried. 




Liked2Think wrote: I again think you are making too much of things as I lost all faith in this company quite some time ago.

I hope you end up being rewarded for your continued faith but I doubt that you will.

Tripp said CARE made $1M a quarter when they were bought I am 100% sure of it.

Lets say he was rounding up like no tomorrow and they actually were making $500,001 a quarter.

That means after 16 months both companies combined made another $500K on top of that.

Makes it sound extremely pathetic.




<< Previous
Bullboard Posts
Next >>